Mirum Pharmaceuticals’ Livmarli approved in the European Union for patients with progressive familial intrahepatic cholestasis

Mirum Pharmaceuticals

8 July 2024 - Mirum Pharmaceuticals today announced that the European Commission has granted marketing authorization for Livmarli (maralixibat) oral solution for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older. 

The approval follows a positive opinion by the CHMP which concluded that Livmarli in progressive familial intrahepatic cholestasis brings significant clinical benefit based on improved efficacy and a major contribution to patient care compared to the existing approved treatment for progressive familial intrahepatic cholestasis.

Read Mirum Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe